Erica Scirocco, Matti D Allen, Elisa Giacomelli, Senda Ajroud-Driss, Jinsy Andrews, Sandra Banack, Peter Bede, Michael Benatar, Ken Cheung, Philippe Corcia, Mamede de Carvalho, Lauren Elman, John K Fink, Angela Genge, Orla Hardiman, Matthew Harms, Daragh Heitzman, Grace Jang, Osamu Kano, Matthew C Kiernan, Ikjae Lee, Albert Ludolph, Paul Mehta, Hande Ozdinler, Kourosh Rezania, Paride Schito, Alexander V Sherman, Vincenzo Silani, Eric Sorenson, Martin R Turner, Leonard Van Den Berg, Hiroshi Mitsumoto, Sabrina Paganoni
{"title":"原发性侧索硬化的治疗试验。","authors":"Erica Scirocco, Matti D Allen, Elisa Giacomelli, Senda Ajroud-Driss, Jinsy Andrews, Sandra Banack, Peter Bede, Michael Benatar, Ken Cheung, Philippe Corcia, Mamede de Carvalho, Lauren Elman, John K Fink, Angela Genge, Orla Hardiman, Matthew Harms, Daragh Heitzman, Grace Jang, Osamu Kano, Matthew C Kiernan, Ikjae Lee, Albert Ludolph, Paul Mehta, Hande Ozdinler, Kourosh Rezania, Paride Schito, Alexander V Sherman, Vincenzo Silani, Eric Sorenson, Martin R Turner, Leonard Van Den Berg, Hiroshi Mitsumoto, Sabrina Paganoni","doi":"10.1080/21678421.2025.2527123","DOIUrl":null,"url":null,"abstract":"<p><p>Primary lateral sclerosis (PLS) is a rare neurodegenerative disorder primarily affecting the upper motor neurons. People living with PLS experience progressive physical and communication disability, which typically evolves slowly over several years. In contrast to amyotrophic lateral sclerosis (ALS), life expectancy is anticipated to be normal. Disease-modifying medications are not available and PLS drug development has been challenging. This review considers recent advances and ongoing initiatives aimed at promoting clinical trial readiness for PLS. Ongoing clinical research efforts include patient registries and biorepositories, natural history studies, outcome measure validation, and biomarker development. These international collaborative efforts are essential for developing the first therapeutic trials for people living with PLS.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":" ","pages":"1-8"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Toward therapeutic trials in primary lateral sclerosis.\",\"authors\":\"Erica Scirocco, Matti D Allen, Elisa Giacomelli, Senda Ajroud-Driss, Jinsy Andrews, Sandra Banack, Peter Bede, Michael Benatar, Ken Cheung, Philippe Corcia, Mamede de Carvalho, Lauren Elman, John K Fink, Angela Genge, Orla Hardiman, Matthew Harms, Daragh Heitzman, Grace Jang, Osamu Kano, Matthew C Kiernan, Ikjae Lee, Albert Ludolph, Paul Mehta, Hande Ozdinler, Kourosh Rezania, Paride Schito, Alexander V Sherman, Vincenzo Silani, Eric Sorenson, Martin R Turner, Leonard Van Den Berg, Hiroshi Mitsumoto, Sabrina Paganoni\",\"doi\":\"10.1080/21678421.2025.2527123\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Primary lateral sclerosis (PLS) is a rare neurodegenerative disorder primarily affecting the upper motor neurons. People living with PLS experience progressive physical and communication disability, which typically evolves slowly over several years. In contrast to amyotrophic lateral sclerosis (ALS), life expectancy is anticipated to be normal. Disease-modifying medications are not available and PLS drug development has been challenging. This review considers recent advances and ongoing initiatives aimed at promoting clinical trial readiness for PLS. Ongoing clinical research efforts include patient registries and biorepositories, natural history studies, outcome measure validation, and biomarker development. These international collaborative efforts are essential for developing the first therapeutic trials for people living with PLS.</p>\",\"PeriodicalId\":72184,\"journal\":{\"name\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21678421.2025.2527123\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2025.2527123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Toward therapeutic trials in primary lateral sclerosis.
Primary lateral sclerosis (PLS) is a rare neurodegenerative disorder primarily affecting the upper motor neurons. People living with PLS experience progressive physical and communication disability, which typically evolves slowly over several years. In contrast to amyotrophic lateral sclerosis (ALS), life expectancy is anticipated to be normal. Disease-modifying medications are not available and PLS drug development has been challenging. This review considers recent advances and ongoing initiatives aimed at promoting clinical trial readiness for PLS. Ongoing clinical research efforts include patient registries and biorepositories, natural history studies, outcome measure validation, and biomarker development. These international collaborative efforts are essential for developing the first therapeutic trials for people living with PLS.